MAPT and Alzheimer disease: CSF biomarkers have been proven useful in AD, where a typical CSF profile of decreased levels of amyloid-β 1–42 (Aβ1–42) combined with increased levels of total and phosphorylated tau (t-tau, p-tau) protein levels supports the diagnosis of AD [6].